The test helps select the right drug for breast cancer patients. Credit: BlurryMe / Shutterstock.com.

Biotech company Heligenics has introduced a new precision genetic test to choose among drugs for the treatment of breast cancer.

The new genetic test helps select among three drugs approved by the US Food and Drug Administration (FDA) for breast cancer.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company began with the drugs, Tykerb, Nerlynx and Tukysa.

Heligenics stated that there are more than 10,000 potential mutations in a cancer gene and it is difficult to identify which one produces resistance.

Its GigaAssay technology will help quickly identify specific mutations among thousands for which a breast cancer patient is susceptible to a desired drug.

See Also:

The company can also detect which of these variants produces resistance to the drug.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It intends to select commercial partners who can run a prospective study, receive approval from the FDA and launch the test in the market.

According to the company, the new test is anticipated to revolutionise the analysis of biopsies to establish a data-driven approach to treatment. 

Heligenics board member Dr Jerome Rotter said: “This test is a great example of the future of personalised drug therapy.”

The company has expertise in functional genomics research and services, offering comprehensive genomic solutions to healthcare providers, biotech and pharmaceutical companies.

Furthermore, the company develops cell-based GigaAssays to evaluate gene function and provide custom services in drug development and molecular diagnostics.